Document Type
Rapid Review
Review Code
EOC011101 RR
Question Submitted
January 11, 2021
Date Completed
January 13, 2021
Status
3. Completed
Research Team
EOC
Document Type
Rapid Review
Review Code
EOC011101 RR
Question Submitted
January 11, 2021
Date Completed
January 13, 2021
Status
3. Completed
Research Team
EOC
Key Findings
Overall, data are insufficient to recommend for or against the use of ECMO in patients with COVID-19 and refractory hypoxemia.
The best available evidence points to an overall combined mortality rate of 46% among COVID-19 patients placed on ECMO (n=331). This rate is similar to the overall 40% mortality rate for extracorporeal life support in pulmonary failure. However, mortality rates among COVID-19 patients on ECMO range widely due to patient factors, site specific factors, and small sample sizes in available studies.
Recommendations for strategies and patient indications/contraindications are available to help guide centres intending to offer ECMO to COVID-19 patients.
Category
Clinical Management
Healthcare Services
Subject
Critical Care
Treatment
Population
All
Clinical Setting
ICU
Priority Level
Level 2 One week (7 days)
Cite As
Vanstone, J; Groot, G; Dalidowicz, M; Young, C. What are the outcomes of ECMO and COVID, particularly in small centers? 2021 Jan 13; Document no.: EOC011101 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 7 p. (CEST rapid review report)
Related Documents
Documents
Less detail